Literature DB >> 10320241

Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial.

M Ranucci1, A Mazzucco, R Pessotto, G Grillone, V Casati, L Porreca, R Maugeri, M Meli, P Magagna, S Cirri, P Giomarelli, R Lorusso, A de Jong.   

Abstract

BACKGROUND: Heparin-coated circuits (HCCs) in low-risk cardiac patients who have coronary revascularization have a limited impact on postoperative outcome. In this prospective, randomized investigation, we studied high-risk patients who had cardiac operations with or without HCCs.
METHODS: A total of 886 patients who had cardiac operations with cardiopulmonary bypass and at least one patient-related or procedure-related risk factor were enrolled in a multicenter study. They were randomly allocated to have cardiopulmonary bypass with Duraflo II HCCs (HCC group, n = 442) or conventional circuits (control group, n = 444). Postoperative outcome was investigated with respect to the occurrence of organ dysfunction.
RESULTS: HCCs are associated with a shorter intensive care unit and postoperative hospital stay and with a lower rate of patients having a severely impaired clinical outcome (stay in intensive care unit for more than 5 days or death) (relative risk 0.66, p = 0.045). Lung dysfunction rate was significantly lower for the patients in HCC group affected by chronic obstructive pulmonary disease or who had mitral procedure (relative risk, respectively, 0.31, p = 0.018 and 0.05, p = 0.02). Renal dysfunction rate was significantly (p = 0.05) lower for diabetics in the HCC group (relative risk 0.28).
CONCLUSIONS: When HCCs were used postoperative times decreased and they had a protective effect on lung and kidney function in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10320241     DOI: 10.1016/s0003-4975(99)00062-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Thromboresistant cardiopulmonary bypass circuits: room for improvement?

Authors:  Jeffrey A Poynter
Journal:  J Surg Res       Date:  2010-03-19       Impact factor: 2.192

2.  The efficacy of parecoxib on systemic inflammatory response associated with cardiopulmonary bypass during cardiac surgery.

Authors:  Qingping Wu; Gunsham Purusram; Huiqing Wang; Ruixia Yuan; Wanli Xie; Ping Gui; Nianguo Dong; Shanglong Yao
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

3.  Minimally invasive cardiopulmonary bypass: does it really change the outcome?

Authors:  Marco Ranucci; Giuseppe Isgrò
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

4.  Safety and efficacy of biocompatible perfusion strategy in a contemporary series of patients undergoing coronary artery bypass grafting - a two-center study.

Authors:  Oz M Shapira; Amit Korach; Frederic Pinaud; Abeer Dabah; Yusheng Bao; Jean Jacques Corbeau; Jean-Louis de Brux; Christophe Baufreton
Journal:  J Cardiothorac Surg       Date:  2014-12-18       Impact factor: 1.637

5.  Postoperative hypoxia and length of intensive care unit stay after cardiac surgery: the underweight paradox?

Authors:  Marco Ranucci; Andrea Ballotta; Maria Teresa La Rovere; Serenella Castelvecchio
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 6.  Basics of cardiopulmonary bypass.

Authors:  Manjula Sarkar; Vishal Prabhu
Journal:  Indian J Anaesth       Date:  2017-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.